Clinical Trial Update: A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and local tolerability of escalating doses of a long-acting activated recombinant human Factor VII in healthy male volunte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorders
• Hemophilia

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED